🇺🇸 Metolazone Tablets in United States

32 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 32

Most-reported reactions

1. Nausea — 5 reports (15.62%)
2. Dehydration — 4 reports (12.5%)
3. Dizziness — 4 reports (12.5%)
4. Decreased Appetite — 3 reports (9.38%)
5. Disease Progression — 3 reports (9.38%)
6. Dyspnoea — 3 reports (9.38%)
7. Fatigue — 3 reports (9.38%)
8. Headache — 3 reports (9.38%)
9. Asthenia — 2 reports (6.25%)
10. Blood Electrolytes Decreased — 2 reports (6.25%)

Source database →

Frequently asked questions

Is Metolazone Tablets approved in United States?

Metolazone Tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Metolazone Tablets in United States?

NHS Greater Glasgow and Clyde is the originator. The local marketing authorisation holder may differ — check the official source linked above.